Systematic Review of Efficacy and Safety of Semaglutide in the Treatment of Type 2 Diabetes Mellitus

HU Jinhua; HAN Jingjie; JIN Min; ZENG Fang; HU Bin; LOU Yuefen

doi:10.14009/j.issn.1672-2124.2022.09.021

您当前的位置：

首页 >

文章列表页 >

Systematic Review of Efficacy and Safety of Semaglutide in the Treatment of Type 2 Diabetes Mellitus

更新时间：2023-04-16

- Systematic Review of Efficacy and Safety of Semaglutide in the Treatment of Type 2 Diabetes Mellitus
- Vol. 22, Issue 9, Pages: 1114-1121(2022)
- 作者机构：
  
  同济大学附属上海市第四人民医院药剂科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.09.021
  CLC： R969.3
- Published：2022，
扫描看全文
HU Jinhua, HAN Jingjie, JIN Min, et al. Systematic Review of Efficacy and Safety of Semaglutide in the Treatment of Type 2 Diabetes Mellitus. [J]. 22(9):1114-1121(2022)
DOI：

HU Jinhua, HAN Jingjie, JIN Min, et al. Systematic Review of Efficacy and Safety of Semaglutide in the Treatment of Type 2 Diabetes Mellitus. [J]. 22(9):1114-1121(2022) DOI： 10.14009/j.issn.1672-2124.2022.09.021.

摘要

目的：评价索马鲁肽治疗2型糖尿病的疗效和不良反应。方法：检索建库至2021年7月中国知网、中国生物医学文献、万方数据库、维普数据库、PubMed、Embase、the Cochrance Library、Web of science和ClinicalTrials.gov数据库发表的索马鲁肽对比安慰剂治疗2型糖尿病的随机对照试验(RCT)

对纳入研究的质量进行评价并提取数据。Meta分析采用Stata 16和RevMan 5.3软件进行。结果：共纳入11项RCT

包括5 753例患者。分析结果表明，与安慰剂相比，索马鲁肽降糖、减重效果显著，可降低2型糖尿病患者的糖化血红蛋白(HbA

c)水平(MD=-1.18

95%CI=-1.35～-1.02

0.000 1)、空腹血糖水平(MD=-1.65

95%CI=-1.95～-1.36

0.000 1)和体重(MD=-3.06

95%CI=-3.94～-2.19

0.000 01)

同时可显著提高患者的HbA

c达标率(HbA

6.5%达标率：RR=5.57

95%CI=4.06～7.63

0.000 01;HbA

7.0%达标率：RR=3.55

95%CI=2.88～4.36

0.000 01)

还可降低收缩压水平(MD=-3.16

95%CI=-4.30～-2.02

0.000 01)

上述差异均有统计学意义。与安慰剂相比，索马鲁肽的不良事件发生率略高(RR=1.09

95%CI=1.05～1.13

0.000 1)

其中胃肠道反应最为常见(RR=1.95

95%CI=1.73～2.20

0.000 01)

但严重不良事件发生率(RR=0.98

95%CI=0.80～1.20

P=0.83)和低血糖发生率(RD=-0.00

95%CI=-0.03～0.02

P=0.78)与安慰剂相似。结论：索马鲁肽较安慰剂有显著的降糖、减重作用，索马鲁肽发生低血糖的风险较低，胃肠道反应为其主要不良反应，但一般症状较轻。

Abstract

OBJECTIVE: To evaluate the efficacy

safety and adverse drug reactions of semaglutide in the treatment of type 2 diabetes mellitus. METHODS: CNKI

CBM

Wanfang Data

VIP

PubMed

Embase

the Cochrance Library

Web of science and ClinicalTrials.gov databases were retrieved to collect the randomized controlled trial（RCT） of semaglutide versus placebo in the treatment of type 2 diabetes mellitus. Evaluation of the quality of included literature and extraction of data were performed. Meta-analysis was performed by using Stata 16 and RevMan 5.3 software. RESULTS: A total of 11 RCT were enrolled

including 5 753 patients. Compared with placebo

semaglutide had significant effect on hypoglycemic and weight loss

and could reduce the glycosylated hemoglobin（HbA

c） level（MD=-1.18

95%CI=-1.35--1.02

0.000 1）

fasting blood glucose level（MD=-1.65

95%CI=-1.95--1.36

0.000 1） and body weight（MD=-3.06

95%CI=-3.94--2.19

0.000 01）

significantly increase the HbA

c compliance rate（control rate of HbA

6.5%:RR=5.57

95%CI=4.06-7.63

0.000 01;control rate of HbA

7.0%:RR=3.55

95%CI=2.88-4.36

0.000 01）

decrease the systolic blood pressure（MD=-3.16

95%CI=-4.30--2.02

0.000 01） in patients with type 2 diabetes mellitus

the differences were statistically significant. Compared with placebo

semaglutide had slightly higher incidence of adverse events（RR=1.09

95%CI=1.05-1.13

0.000 1）

of which gastrointestinal reactions were the most common（RR=1.95

95%CI=1.73-2.20

0.000 01）. However

the incidence of severe adverse events（RR=0.98

95%CI=0.80-1.20

P=0.83） and hypoglycemia（RD=-0.00

95%CI=-0.03-0.02

P=0.78） were similar to those of placebo. CONCLUSIONS: Compared with placebo

semaglutide has significant hypoglycemic and weight loss effect. Semaglutide has a lower risk of hypoglycemia. Gastrointestinal reactions are the main adverse drug reactions of semaglutide

yet the symptoms are generally mild.

关键词

索马鲁肽2型糖尿病Meta分析

Keywords

SemaglutideType 2 diabetes mellitusMeta-analysis

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Systematic Review of Huisheng Oral Liquid on Coagulation Function, Efficacy and Safety of Patients with Non-Small Cell Lung Cancer

Systematic Review of Efficacy and Safety of Dantian Jiangzhi Pills Combined with Statins in the Treatment of Hyperlipidemia

Systematic Review of Clinical Efficacy and Safety of Formula Granules of Liangfu Pill in the Treatment of Epigastric Pain

Systematic Review of Runzao Zhiyang Capsules Combined with Antihistamine in the Treatment of Chronic Urticaria

Meta-Analysis of Efficacy and Safety of Ticagrelor Combined with Rosuvastatin Therapy in the Treatment of Unstable Angina Pectoris

Related Author

ZHANG Jinhua

TIAN Yuan

YANG Xiaoping

ZHANG Yi

LIU Wei

LI Xingxing

FAN Zongjing

CUI Jie

Related Institution

Dept. of Oncology, Jingmen First People’s Hospital

Traditional Chinese Medicine Phenomics Research Center, Traditional Chinese Medicine Hospital Affiliated to Southwest Medical University

Dept. of Internal Medicine of Traditional Chinese Medicine, Shanghai Seventh People’s Hospital

Dept. of Internal Medicine of Traditional Chinese Medicine, Shanghai Tongren Hospital

Second School of Clinical Medicine, Beijing University of Chinese Medicine

⁰